RxDoctor Payments Data

Christine Tressel, DO

Family Medicine · West Chester, PANPI 1881624948

Payments from drug & device makers

$718in general payments, 2019–2025

Across 36 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$182
  • Amgen$170
  • GSK$83
  • Novo Nordisk$78
  • Pfizer$61
  • Sanofi Pasteur Inc.$49
  • plus $94 from 5 others

What the payments were for

  • Food & beverage$718100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$718 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$64,974
Medicare patients
329
Services billed
1,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate18$20,520
JardianceEmpagliflozin11$17,368
OzempicSemaglutide12$16,404
Rosuvastatin Calcium148$2,769
Atorvastatin Calcium177$1,702
Levothyroxine Sodium173$1,684
Esomeprazole Magnesium13$1,470
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine17$1,309
Fluticasone Propionate45$1,191
Metformin Hcl ErMetformin Hcl98$1,174
Simvastatin140$1,172
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide24$1,141
Losartan Potassium88$1,036
Lisinopril148$1,002
Metoprolol Succinate58$926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$12$20,52018 claims
Novo NordiskOzempic$78$16,40412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in West Chester

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →